SEC Form 3 · accession 0001104659-17-004382
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Kamen
Director
Period of report
Jan 26, 2017
Accepted (ET)
Jan 26, 2017 · 9:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 60,975 | D | ||
| Common StockF1,F2 | holding | — | — | — | 33,875 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $9.56 | holding | — | — | — | — | Oct 24, 2026 | Common Stock | 10,840 | — | D |
Explanation of responses
- F1The Reporting Person was granted a) 67,750 restricted shares on February 6, 2013, which vested as to 50% of the shares on the date of grant and the remaining 50% of the shares vested in six equal quarterly installments after February 1, 2014; and b) 27,100 restricted shares on June 20, 2013, which vest in 16 quarterly installments from June 20, 2013.
- F2Shares held by The Robert Kamen 2012 Irrevocable Trust, of which the Reporting Person's spouse is a trustee.
- F3The option shares vest and become exercisable in 16 quarterly installments from October 24, 2016.
Remarks
Exhibit 24.1: Limited Power of Attorney